Jinwon Life Sciences announced on the 30th that it has signed a plasmid DNA pharmaceutical supply contract worth 2.7 million dollars with a U.S. biotech company.
A company representative explained, "The name of the contracting party cannot be disclosed due to a confidentiality clause in the contract, and when converted to Korean won, the contract amount is approximately 3.8 billion won."
Park Young-geun, CEO of Jinwon Life Sciences, said, "Based on the differentiated large-scale, high-quality plasmid DNA production capabilities of our subsidiary VGXI, we have been expanding our sales force and conducting aggressive marketing, resulting in visible achievements leading to the signing of contract manufacturing agreements."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
